Labiotech.eu

Covid vaccine lawsuit: Moderna vs Pfizer

News and Trends 26 Aug 2022

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine Comirnaty infringes patents it led between 2010 and 2016 covering Moderna’s foundational mRNA technology which the company says was critical to the development of its own […]

August 26, 2022 - 4 minutesmins - By Liza Laws

Startup Scout 26 Aug 2022

Epic Bio makes gene therapies by editing the epigenome

CRISPR-Cas9 genome editing has changed the game for gene therapy, but carries safety risks when cutting DNA. The new U.S. firm Epic Bio aims to reduce these risks by targeting epigenetic controls on gene expression. The development of the genome-editing tool CRISPR-Cas9 caused a paradigm shift in the biotech industry because it made it easier […]

August 26, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 26 Aug 2022

Swedish researchers developing new treatment for chronic hepatitis B and D infections

A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet in Sweden, have been published in the journal Gut. Chronic infections of the hepatitis B virus (HBV) and hepatitis […]

August 26, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Aug 2022

Aktis Oncology raises millions in funding bringing total to $161M

Aktis Oncology announced yesterday (August 25) that it has raised a series A extension financing of $84 million bringing its total capital raised to date to $161 million. The Massachusetts-based company develops targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. Aktis Oncology‘s investors The extension included participation from new health investors Cowen […]

August 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […]

August 26, 2022

News and Trends 26 Aug 2022

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

Antibodies that target a protein playing a key role in the regulation of cholesterol levels have been introduced by Bio-Rad Laboratories. The range of type 1 antibodies inhibit the binding of evolocumab (Repatha) to its target – human proprotein convertase subtilisin/kevin type 9 (PCSK9). Recombinant antibodies These sequence-defined, recombinant antibodies are suitable for developing highly […]

August 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

First gene therapy for adults with severe hemophilia approved by EC

The European Commission (EC) has granted conditional marketing authorization for a gene therapy to treat severe hemophilia A in adults it was announced yesterday (August 25). BioMarin Pharmaceutical Inc.’s Roctavian (valoctocogene roxaparvovec) treats the congenital factor 8 deficiency in adults patients without a history of factor VIII inhibitors without detectable antibodies to adeno-associated virus serotype […]

August 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

Ordaōs raises $5M to accelerate drug design and discovery

U.S. biotech company Ordaōs has raised $5 million in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a drug design company that […]

August 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Biotech stocks enjoy brief rally with uncertain winds ahead

Global biotech stocks have briefly risen after sinking steadily over the last year. Whether this recovery lasts is another question. Here are the latest biotech stock trends for 2022. In early 2021, biotech stock markets began a long period where stocks dropped in value caused by investors fleeing the sector. This season, known as a […]

August 25, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 25 Aug 2022

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […]

August 25, 2022 - 3 minutesmins - By Liza Laws

Best in Biotech 25 Aug 2022

Five cleantech companies making New Zealand more green

Cleantechs are focused on reducing negative environmental impacts by offering recycling, renewable energy, green chemistry solutions and more. From extracting gold from old electronics to seaweed supplements for cattle, here are five cleantech companies hailing from New Zealand. New Zealand has been ranked fourth in the world for biotechnology innovation potential. By leveraging the country’s […]

August 25, 2022 - 4 minutesmins - By Omnia Ibrahim

coronavirus COVID 19 Europe biotech lungs

News and Trends 25 Aug 2022

Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer

Patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases have completed their last visit in a clinical trial studying the drug, Zorifertinib. Drugs developer, Alpha Biopharma, announced the completion today (August 25) of last patient last visit (LPLV) in its international, multicenter EVEREST phase 2/3 study of the next-generation […]

August 25, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Epic Bio makes gene therapies by editing the epigenome

Swedish researchers developing new treatment for chronic hepatitis B and D infections

Aktis Oncology raises millions in funding bringing total to $161M

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

First gene therapy for adults with severe hemophilia approved by EC

Ordaōs raises $5M to accelerate drug design and discovery

Biotech stocks enjoy brief rally with uncertain winds ahead

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

Five cleantech companies making New Zealand more green

Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!